ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Japan approves AstraZeneca's Tagrisso in EGFRm non-small cell lung cancer
August 22, 2018AstraZeneca has revealed that its EGFR tyrosine kinase inhibitor Tagrisso (osimertinib) has been approved in Japan by the nation’s Ministry of Health, Labour and Welfare (MHLW) as a first-line therapy in patients with inoperable or recurrent epidermal gro
Pharma Sources Insight January 2025
